The first batch of Gem 16 released in the report 15 growth 1 face

Intermediary transaction SEO diagnosis Taobao guest Cloud host technology Hall

Into the middle of August, means that the listed companies in the report of the performance disclosure time is nearing the end, in the thousands of companies to hand over the report card, while the growth of the concept of the first batch of the 28 companies in the company's report results are of great concern. According to wind data statistics show that as of yesterday, 16 companies in the first 28 companies issued interim results reports, of which 15 companies reported year-on-year growth, 1 performance, net profit growth was negative, in 15 of the growth of companies, only 1 companies to increase the performance of more than 100%.

Huayi Brothers rose for the first

As the first batch of gem companies, in the "three high" background, the company listed all raised the enterprise development of huge capital, however, their growth is often subject to market considerations. Although 28 of the first gem companies reported the results of the report has been more than half, however, the performance growth of more than 50% of the only 5, in addition to Huayi brothers growth of more than 100%, billion-Wei Li, Huawei Electronics, robotics, AI-er, four companies in the first half of the net profit growth in the same period of 85.56%, 82.1%, 53.85% and 52.6%. It is worth noting that the first half of Huaxing's performance growth was only 3.68%.

As the first batch of 28 gem companies in the paper not all out, therefore, in the 16 companies have been released, the biggest performance growth is Huayi Brothers, the first half of the company to achieve net profit of 63.649 million yuan, the year-on-year growth of 125.09%, earnings per share 0.11 yuan. The first half of the company's operating income 330 million yuan, an increase of 63.24%.

For the growth of performance, the company said, operating income, net profit growth is the main reason for the company after the listing, in strict accordance with the fund-raising plan to expand the company's main business plate production scale, product sales trend is good; the operating income and profit of the company's film business have increased significantly compared with the same period The scope of corporate consolidation has changed.

In addition, according to 16 reports, the largest net profit of the company when the general medical care, the first half of the company to achieve net profit of 260 million yuan, 16 companies to become the largest net profit company, become a veritable gem "Performance King."

North Road Pharmaceutical net profit falls 13.33%

As a financing platform, the capital market to meet the needs of enterprise financing, but the capital market is also a big market to optimize Amoy, the quality of the company, will be in the capital market this big furnace refining. Therefore, when the listed company publishes the performance announcement, the performance is good or bad to explain everything.

In the release of the interim results of the 16 first gem companies, in addition to huaxing entrepreneurial performance growth of only 3.68%, at a low level of growth, the first half of the northern pharmaceutical industry's performance growth directly in negative statements. According to the company reported that the first half of the company's shareholders net profit of 19.5829 million yuan, down 13.36% per cent, earnings for each share of 0.13 yuan, down 13.33% year-on-year.

For the decline in performance, the company said that during the reporting period with the company's continuous investment in marketing network construction, the volume of business compared with the same period a year ago, and the company implemented a sales and business separation of professional marketing model. Sales volume expansion, sales and business staff growth, resulting in the reporting period of sales costs compared with the same period of 97.93% increase, is the company's operating profit and total profit lower than a year ago the main reason.

If nearly twice the cost of sales has led to a decline in net profits, the resignation of executives at the end of the first half of the year has also left investors daydreaming.

June 30, the company's director of research and Development deputy general manager Ge Jian resigned, and resigned the reason is "concept gap", it is worth mentioning that Ge Jianlai company only 4 months.

In the Northern China pharmaceutical industry released a decline in the reporting period, the executive management of research and development of the resignation may be a coincidence, in this respect, the North land pharmaceutical industry also said that Ge Jian's departure will not have a substantial impact on the company's core competitiveness.

In addition, for the listed companies, performance growth in the enterprise to bring sufficient funds, but also to the shareholders to bring high returns, and the listed company's dividend is a shareholder's benefits to maximize the return, in 16 issued the first batch of enterprise Board companies, only one issued a dividend program.

In the first half of the year, the company achieved net profit of 79.8329 million yuan, an increase of 52.63% per share, and 0.3 yuan each, and 6 shares per 10 shares.